SUMMARY The antiarrhythmic effects of amiodarone and verapamil were compared in 19 patients with hypertrophic cardiomyopathy complicated by refractory arrhythmias. While verapamil did not reduce the incidence of arrhythmia, amiodarone abolished ventricular tachycardia in 10 of 13 patients and significantly reduced the number of ventricular extrasystoles. In addition, sinus rhythm was restored by amiodarone in three of five patients with longstanding atrial fibrillation.
Death is a common complication of hypertrophic cardiomyopathy and is usually sudden and unexpected. [1] [2] [3] Serious ventricular arrhythmia is also common,4 and is associated with sudden death. 5 During the past decade beta-adrenergic blockers have been the mainstay of treatment. While they appear to relieve symptoms they do not reduce the incidence of arrhythmia.6 Verapamil, which has been advocated, may improve symptoms and exercise tolerance7 and possibly influence myocardial hypertrophy8 9 but there is little knowledge of the antiarrhythmic effect of this drug in this disease. Amiodarone is effective in a wide variety of ventricular10 and supraventricular arrhythmias. I We therefore decided to compare amiodarone and verapamil in the treatment of arrhythmia in hypertrophic cardiomyopathy.
Methods
Routine 24-hour ambulatory electrocardiographic monitoring is performed at least once a year in patients with hypertrophic cardiomyopathy followed up at the Hammersmith Hospital. Patients were selected for this study if electrocardiographic monitoring disclosed: (1) paroxysmal atrial fibrillation or supraventricular tachycardia; (2) atrial fibrillation with a rapid ventricular response (greater than 100 a minute) despite treatment with digoxin and beta-adrenergic blockers; (3) frequent or complex ventricular extrasystoles or ventricular tachycardia.
All drugs except diuretics were stopped for one week and the following performed at a baseline. (1) *Research Fellow of the Medical Research Council ofCanada. Received for publication 17 February 1981 physical examination including measurement of the blood pressure at rest in the supine position; (2) electrocardiogram and chest x-ray; (3) thyroid and liver function tests; (4) graded maximal treadmill exercise using a modified Bruce protocolt2; (5) (Table 2 ). Nine had episodes of supraventricular tachycardia, of whom five had frequent atrial extrasystoles (>30 an hour). Verapamil produced no significant change in the number of patients with these arrhythmias and the mean daily number ofatrial extrasystoles (295) was unchanged (320). On amiodarone none had supraventricular tachycardia, only one had frequent atrial extrasystoles, and the mean daily number of atrial extrasystoles was significantly reduced during loading (86, p<0 03) and maintenance treatment (20, p<0.001). Five patients were in atrial fibrillation, all for at least five years: in three sinus rhythm was restored during the loading period and in two it was maintained at six months ( Fig.) . Experience with the ventricular arrhythmias detected during ambulatory electrocardiographic monitoring is presented in Table 3 . Nine patients had frequent ventricular extrasystoles (>30 an hour) and 10 had ventricular tachycardia while not being treated. Amiodarone (both loading and maintenance doses) significantly reduced the number of patients who had frequent ventricular extrasystoles and the number with ventricular tachycardia whereas verapamil did not.
The majority of patients with ventricular tachycardia did not have severe symptoms (Table 4) : 11 experienced dyspnoea exclusively during moderate exercise, only three had, syncopal episodes, and one patient was asymptomatic. Their mean left ventricular end-diastolic pressure was 17 mmHg, identical to that found in our series of 254 patients with hypertrophic cardiomyopathy.3 The mean number of episodes of ventricular tachycardia off medication (5 2) and during verapamil (6 1) was similar but was *p<0-00l. **p<0-002. ***p<0.Ol. significantly reduced during amiodarone (less than 1) (p<0001) ( Table 4 ). The average daily number of ventricular extrasystoles off treatment (350) was unchanged on verapamil (435) but was significantly reduced during amiodarone (loading 56, p<0 001; maintenance 105, p<0 001).
During treadmill exercise testing (Table 5 ) the mean resting and maximum heart rates were significantly reduced on both verapamil and amiodarone. The mean duration of exercise, however, was similar during the four treatment periods. During maximal exercise one patient, who did not have ventricular tachycardia on ambulatory monitoring, developed this arrhythmia while on verapamil. In addition, 14 had uniform ventricular extrasystoles but none developed supraventricular tachycardia or more serious ventricular arrhythmias.
Discussion
Although symptoms may be severe, the most important clinical problem in hypertrophic cardiomyopathy is the prevention of sudden death: 30% of patients die suddenly before the age of 30.3 While beta-adrenergic blocking agents improve symptoms and are widely used they do not appear to have prevented sudden death.3 In our series, 23 of 32 patients who died suddenly had been taking propranolol (mean 240 mg daily) for at least three years. 3 Recently verapamil had been advocated to improve symptoms, to increase exercise tolerance, and possibly to reverse myocardial hypertrophy.79 Verapamil is a slow channel blocker and its main electrophysiological action is on the atrioventricular node. 17 Because after-depolarisations and triggered activa-tions are suppressed by verapamil it has been suggested that some ventricular tachycardias might respond to it. 18 The in vitro effects of verapamil on muscle thickness and arrhythmia provide an attractive theoretical basis for treatment in hypertrophic cardiomyopathy. These desirable antiarrhythmic effects were not, however, seen with this drug; seven of eight patients continued to have ventricular tachycardia and three further patients appeared to develop more ventricular arrhythmias on verapamil.
Although clinical studies suggest attenuation of the electrocardiographic9 and echocardiographic8 features of ventricular hypertrophy on verapamil, the natural history of ventricular hypertrophy in hypertrophic cardiomyopathy is variable and the relation of hypertrophy to sudden death is problematic. Of the patients who die suddenly many have massive myocardial hypertrophy,2 but others have near-normal heart weights as well as near-normal echocardiographic indices of wall thickness.19 Serious ventricular arrhythmia is common4 and associated with sudden death;5 such arrhythmia is positively correlated with impaired septal motion but not with ventricular wall thickness.20 What then are the important determinates of prognosis? Clinical manifestation of the disease in childhood,3 a family history ofhypertophic cardiomyopathy and sudden death,3 19 rapidly progressive disease,3 and multiform and pairs of ventricular extrasystoles or ventricular tachycardia during electrocardiographic monitoring5 are associated with sudden death. The antiarrhythmic action of amiodarone appears to result from prolongation of the duration of the action potential. 21 The electrophysiological action is seen as prolongation of refractoriness of both atrial and ventricular myocardium22; so it seemed appropriate to investigate this aspect of its activity in hypertrophic cardiomyopathy. In 13 patients with refractory ventricular arrhythmia, we observed abolition ofventricular tachycardia after amiodarone in 10, and a significant reduction in the number of patients with either frequent or "high grade" ventricular extrasystoles. In addition three of the five patients who had longstanding atrial fibrillation reverted to and have remained in sinus rhythm. Regularisation of the heart rate and restoration of the contribution of atrial contraction to diastolic filling may be particularly beneficial in hypertrophic cardiomyopathy where diastolic filling may be a major determinant of systolic function. 23 Further studies to assess these haemodynamic effects ofamiodarone therapy are needed and longer observation is required to determine whether suppression of ventricular arrhythmia with amiodarone will be maintained and if it will improve prognosis. 
